Table 2.

Primary and secondary outcomes

			Dapagliflozin (n=625)	Placebo (n=625)	HR, RR, or WR (95% CI)*	p value
Primary outcomes
Prevention composite outcome			70 (11·2%)	86 (13·8%)	HR 0·80 (0·58–1·10)	0·17
	New or worsening organ dysfunction		64 (10·2%)	80 (12·8%)	HR 0·80 (0·57–1·11)	NA
		Respiratory decompensation	58 (9·3%)	70 (11·2%)	HR 0·85 (0·60–1·20)	NA
		Cardiovascular decompensation	47 (7·5%)	58 (9·3%)	HR 0·81 (0·55–1·19)	NA
		Kidney decompensation	24 (3·8%)	35 (5·6%)	HR 0·65 (0·38–1·10)	NA
	Death from any cause†		41 (6·6%)	54 (8·6%)	HR 0·77 (0·52–1·16)	NA
Hierarchical composite recovery outcome‡			547 (87·5%)	532 (85·1%)	WR 1·09 (0·97–1·22)	0·14
Secondary outcomes
Composite of acute kidney injury, initiation of renal-replacement therapy, or death from any cause			48 (7·7%)	65 (10·4%)	HR 0·74 (0·50–1·07)	NA
Total number of days alive and free from mechanical ventilation§			554 (88·6%)	540 (86·4%)	WR 1·03 (0·92–1·15)	NA
Total number of days alive, not in the ICU, and free from mechanical ventilation¶			539 (86·2%)	528 (84·5%)	WR 1·02 (0·92–1·14)	NA
Hospital discharge			567 (90·7%)	556 (89·0%)	RR 1·05 (0·94–1·18)	NA

HR=hazard ratio. RR=rate ratio. WR=win ratio. ICU=intensive care unit. NA=not applicable.

^*HR >1 favours placebo, RR >1 favours dapagliflozin, WR >1 favours dapagliflozin.

^†The outcome of death from any cause was also a separate secondary outcome.

^‡The number of patients experiencing improvement by day 30 compared with baseline (discharged from hospital without a worsening event and alive, or still in hospital without a worsening event and without oxygen support) in the hierarchical composite endpoint analysis.

^§The number of patients alive and without any ventilator use during 30 days, in the total number of days analysis.

^¶The number of patients alive and without any ventilator and ICU use during 30 days, in the total number of days analysis.